Bifogade filer
Dicot Pharma submits new patent application for LIB-01 based on positive phase 2a results showing long-term effect
Prenumeration
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Läkemedel & Handel |
Intresserad av bolagets nyckeltal?
Analysera bolaget i Börsdata!
Vem äger bolaget?
All ägardata du vill ha finns i Holdings!
Uppsala, Sweden, November 21, 2025. Dicot Pharma AB today announces that the company has submitted a patent application to strengthen and prolong the intellectual property for the drug candidate LIB-01. The new patent application is based on the long-term effect documented in the recently concluded clinical phase 2a study, a feature that significantly distinguishes LIB-01 from current treatments of erectile dysfunction.
Dicot Pharma's clinical phase 2a study of LIB-01 aimed to evaluate the safety and efficacy in patients with mild to moderate erectile dysfunction. On October 23, 2025, the company presented positive results from the study, showing that the two higher doses, 25 and 50 mg, provided clinically relevant improvements in both patient groups (mild to moderate erectile dysfunction), an effect that is also maintained eight weeks after treatment.
Based on the study results, Dicot Pharma has submitted a new patent application to further strengthen and extend the company's patent protection, which currently lasts until 2042. A priority application has been submitted to the Swedish Patent and Registration Office, PRV, and will be taken forward to an international Patent Cooperation Treaty application within 12 months. The Patent Cooperation Treaty, PCT, covers 158 countries, including relevant key markets for LIB-01.
“The results from the phase 2a study show that LIB-01 has a unique long-term effect that persists for eight weeks after only a three-day treatment. This is significantly different from today's short-acting treatments for erectile dysfunction and may represent a paradigm shift for the treatment of erection problems. This patent application, which is based on the new study results, thus further increases the commercial potential of our drug candidate,” says Elin Trampe, CEO of Dicot Pharma.
The results from the phase 2a study will form the basis for the continued development of LIB-01, and a clinical phase 2b study is planned to begin in 2026.
Read more about the results from the clinical phase 2a study here DICOT PHARMA WEBPAGE.